Novartis at ESMO

Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)

Sep 17, 2020

Novartis 2020 ESMO Annual Meeting Virtual Portal

We are boldly reimagining cancer and blood disorders.

Enter Portal

Press releases

Novartis announces new survival data for its treatment for advanced breast cancer with a specific mutation will be presented at the ESMO Virtual Congress 2020
Novartis reports late-breaking data from Phase III study in advanced melanoma
Novartis announces its advanced breast cancer treatment receives highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale

Source URL:

https://prod1.novartis.com/news/novartis-esmo

List of links present in page

https://prod1.novartis.com/news/novartis-esmo

https://www.virtualcongress.novartis.com/esmo20/?utm_medium=referral&utm_source=novartis.com&utm_campaign=corporate_website_post_oncology

https://prod1.novartis.com/news/media-releases/novartis-kisqali-demonstrates-nearly-five-years-median-overall-survival-metastatic-breast-cancer

https://prod1.novartis.com/news/media-releases/novartis-reports-late-breaking-data-from-phase-iii-combi-i-trial-spartalizumab-pdr001-tafinlar-and-mekinist-advanced-melanoma

https://prod1.novartis.com/news/media-releases/novartis-kisqali-receives-highest-rating-any-cdk46-inhibitor-esmo-magnitude-clinical-benefit-scale